文献速递淋巴瘤

APR-246触发具有不同TP53突变的弥漫大B细胞淋巴瘤细胞的铁蛋白自噬和铁死亡

APR-246 triggers ferritinophagy and ferroptosis of diffuse large B-cell lymphoma cells with distinct TP53 mutations.
PubMed 文献 · Leukemia · 2022-07-14

研究整合2464例弥漫大B细胞淋巴瘤(DLBCL)病例,分析TP53突变类型、定位与临床影响,并在TP53突变DLBCL细胞及异种移植小鼠模型中探索APR-246的抗肿瘤作用。TP53突变频率为16%,与较差的总生存(OS)和无进展生存(PFS)相关;APR-246可诱导第7外显子错义突变细胞的p53依赖性铁蛋白自噬,以及野生型TP53和其他TP53突变细胞的铁死亡。

要点

  • TP53突变频率16%,与DLBCL较差OS和PFS相关,尤其在GCB和UNC亚型。
  • DNA结合域单个TP53突变导致较差OS和PFS;第7外显子突变与更差OS相关,第5和6外显子突变与更差PFS相关。
  • APR-246诱导第7外显子错义突变DLBCL细胞p53依赖性铁蛋白自噬,以及野生型TP53和其他TP53突变细胞铁死亡。

核心结论

  • 第5、6、7外显子的TP53突变是DLBCL进展和生存的预测因素。
  • 通过APR-246靶向突变p53是DLBCL患者有前景的治疗方法。

研究设计与样本

  • 整合来自多个队列(包括本中心)的2464例DLBCL病例,鉴定TP53突变类型、定位及临床影响。
  • 在TP53突变DLBCL细胞和异种移植小鼠模型中应用APR-246探索抗肿瘤效果。

主要发现

  • TP53突变频率为16%,在所有病例中与较差的总生存(OS)和无进展生存(PFS)相关,尤其在生发中心B细胞样(GCB)和未分类(UNC)亚型中。
  • DNA结合域(DBD)的TP53单突变导致较差的OS和PFS。
  • 第7外显子突变与更差的OS相关,第5和6外显子突变与更差的PFS相关。
  • APR-246诱导第7外显子TP53错义突变的DLBCL细胞发生p53依赖性铁蛋白自噬,并诱导携带野生型TP53和其他TP53突变的DLBCL细胞发生铁死亡。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

TP53 mutations correlate with inferior survival in many cancers. APR-246 is a compound to shift mutant p53 and exhibits anti-cancer effects. Among its effects, APR-246 facilitates the binding of restored p53 mutants to target genes and their transcription. A set of 2464 DLBCL cases from multiple cohorts including our center, was integrated to identify the type and localization of TP53 mutations and clinical impacts. APR-246 was applied in TP53-mutated DLBCL cells and xenograft mouse models to explore the anti-tumor effect. TP53 mutations frequency was 16% and TP53 mutations correlated with poor overall survival (OS) and progression-free survival (PFS) in all cases, especially in germinal center B-cell-like (GCB) and unclassified (UNC) subtypes. Notably, TP53 single mutations in the DNA binding domain (DBD) led to poor OS and PFS. Specifically, mutations in exon 7 correlated with poorer OS, while mutations in exons 5 and 6 associated with inferior PFS. APR-246 induces p53-dependent ferritinophagy of DLBCL cells with TP53 missense mutation on exon 7 and ferroptosis of DLBCL cells harboring wild-type TP53 and other TP53 mutations. TP53 mutations on exons 5, 6 and 7 are predictors of progression and survival. Targeting mutant p53 by APR-246 is a promising therapeutic approach for DLBCL patients.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Hong Y, Ren T, Wang X, et al. APR-246 triggers ferritinophagy and ferroptosis of diffuse large B-cell lymphoma cells with distinct TP53 mutations. Leukemia. 2022. PMID: 35835991. doi:10.1038/s41375-022-01634-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。